Log in
NASDAQ:BNTC

BENITEC BIOPHAR/S Stock Forecast, Price & News

$6.77
-0.28 (-3.97 %)
(As of 09/18/2020 12:00 AM ET)
Add
Compare
Today's Range
$5.94
Now: $6.77
$7.05
50-Day Range
$5.66
MA: $7.15
$8.70
52-Week Range
$4.14
Now: $6.77
$17.70
Volume11,393 shs
Average Volume47,169 shs
Market Capitalization$7.50 million
P/E RatioN/A
Dividend YieldN/A
Beta1.71
Benitec Biopharma Limited, a biotechnology company, develops treatments for chronic and life-threatening human diseases based on its gene silencing therapy, DNA-directed RNA interference (ddRNAi) in Australia and the United States. The company provides BB-301, a single administration ddRNAi-based gene therapy for the treatment of oculopharyngeal muscular dystrophy; BB-201, a ddRNAi-based therapy for the treatment of wet age-related macular degeneration; and BB-101 and BB-103 ddRNAi-based therapies for the treatment of human hepatitis B. It also offers BB-401 and BB-501 for the treatment of oncology related to head and neck squamous cell carcinoma. The company was founded in 1995 and is headquartered in North Sydney, Australia.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.3Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.29 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:BNTC
CUSIPN/A
CIKN/A
Phone61-3-8692-7222

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$12.52 million
Cash Flow$4.26 per share
Book Value$19.75 per share

Profitability

Miscellaneous

EmployeesN/A
Market Cap$7.50 million
Next Earnings Date9/24/2020 (Estimated)
OptionableNot Optionable
$6.77
-0.28 (-3.97 %)
(As of 09/18/2020 12:00 AM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive BNTC News and Ratings via Email

Sign-up to receive the latest news and ratings for BNTC and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











BENITEC BIOPHAR/S (NASDAQ:BNTC) Frequently Asked Questions

How has BENITEC BIOPHAR/S's stock price been impacted by Coronavirus (COVID-19)?

BENITEC BIOPHAR/S's stock was trading at $3.83 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, BNTC stock has increased by 76.8% and is now trading at $6.77.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of BENITEC BIOPHAR/S?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for BENITEC BIOPHAR/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for BENITEC BIOPHAR/S
.

When is BENITEC BIOPHAR/S's next earnings date?

BENITEC BIOPHAR/S is scheduled to release its next quarterly earnings announcement on Thursday, September 24th 2020.
View our earnings forecast for BENITEC BIOPHAR/S
.

What price target have analysts set for BNTC?

1 analysts have issued 1-year price objectives for BENITEC BIOPHAR/S's stock. Their forecasts range from $14.00 to $14.00. On average, they anticipate BENITEC BIOPHAR/S's share price to reach $14.00 in the next year. This suggests a possible upside of 106.8% from the stock's current price.
View analysts' price targets for BENITEC BIOPHAR/S
.

Are investors shorting BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S saw a increase in short interest in the month of August. As of August 31st, there was short interest totaling 16,600 shares, an increase of 1,409.1% from the August 15th total of 1,100 shares. Based on an average daily trading volume, of 25,900 shares, the days-to-cover ratio is currently 0.6 days. Currently, 1.0% of the shares of the company are short sold.
View BENITEC BIOPHAR/S's Short Interest
.

Who are some of BENITEC BIOPHAR/S's key competitors?

What other stocks do shareholders of BENITEC BIOPHAR/S own?

Who are BENITEC BIOPHAR/S's key executives?

BENITEC BIOPHAR/S's management team includes the following people:
  • Dr. Jerel A. Banks, CEO & Exec. Chairman
  • Ms. Georgina Kilfoil, Chief Devel. Officer (Age 50)
  • Ms. Megan Joan Boston, Exec. Director & Head of Operations - Australia
  • Mr. Bryan Dulhunty, Chief Financial Officer
  • Dr. Michael Graham, Head of Discovery & Founding Scientist

When did BENITEC BIOPHAR/S IPO?

(BNTC) raised $0 in an IPO on Thursday, August 6th 2015. The company issued 0 shares at a price of $0.00 per share. BMO Capital Markets and Maxim Group LLC acted as the underwriters for the IPO and Roth Capital Partners was co-manager.

What is BENITEC BIOPHAR/S's stock symbol?

BENITEC BIOPHAR/S trades on the NASDAQ under the ticker symbol "BNTC."

Who are BENITEC BIOPHAR/S's major shareholders?

BENITEC BIOPHAR/S's stock is owned by many different institutional and retail investors. Top institutional investors include Sabby Management LLC (1.11%).

Which institutional investors are selling BENITEC BIOPHAR/S stock?

BNTC stock was sold by a variety of institutional investors in the last quarter, including Sabby Management LLC.

How do I buy shares of BENITEC BIOPHAR/S?

Shares of BNTC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is BENITEC BIOPHAR/S's stock price today?

One share of BNTC stock can currently be purchased for approximately $6.77.

How big of a company is BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S has a market capitalization of $7.50 million and generates $12.52 million in revenue each year.

What is BENITEC BIOPHAR/S's official website?

The official website for BENITEC BIOPHAR/S is www.benitec.com.

How can I contact BENITEC BIOPHAR/S?

BENITEC BIOPHAR/S's mailing address is Level 14 114 William St, Melbourne C3, 3000. The biotechnology company can be reached via phone at 61-3-8692-7222 or via email at [email protected]

This page was last updated on 9/19/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.